Full-Time

Director – IT Quality & Compliance

Updated on 3/14/2025

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Compensation Overview

$227k - $264kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position; specific in-office days not mentioned.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree in information technology, compliance, or a related field; Master’s degree preferred, with a minimum of 12 years of experience. Other combinations of education and/or experience may be considered. 5+ years of experience in a managerial role.
  • Experience working with startup Life Science companies.
  • Experience with Veeva Quality Systems mandatory.
  • Experience managing releases and validating GxP applications.
  • Strong understanding and practice of IT methodologies, practices, and tools.
  • Experience validating ERP systems.
  • Experience implementing / managing automated testing tools (suggested).
  • Experience with serialization.
  • Experience in developing policies around data privacy.
  • Familiarity with regulatory standards and their application within IT organizations.
  • Experience managing and motivating blended teams (full-time, matrix, 3rd party).
  • Strong experience in managing projects and delivering to strict deadlines.
  • Analytical mindset with the ability to identify patterns, trends, and potential areas of improvement.
  • Exceptional business partnering skills. Consulting background a strong plus.
  • Experience with Quality and Compliance frameworks and standards and their practical application within IT organizations.
  • Strong communication and interpersonal skills, with the ability to effectively collaborate with technical and non-technical stakeholders.
Responsibilities
  • Lead and support Computer Software Assurance (CSA) activities for new and existing systems, ensuring compliance with GxP standards and 21 CFR Part 11 regulations​​.
  • Assess and manage IT GxP Change Controls, ensuring proper impact assessment, testing, and documentation for any system modifications​​. Monitor and validate IT system changes using defined change control processes.
  • Assess and manage IT risks, implementing strategies to mitigate vulnerabilities.
  • Oversee the development, implementation, and revision of IT SOPs and policies.
  • Evaluate and qualify IT vendors for GxP systems using standardized assessment procedures, including vendor audits and the GxP Software Provider Questionnaire​​.
  • Lead the development of Vaxcyte processes for IT Quality, Compliance, and Cybersecurity.
  • Oversee vendor compliance with Vaxcyte's Quality Management System (QMS) and regulatory standards​.
  • Conduct IT vendor evaluations, ensuring compliance with Vaxcyte’s Vendor Management Program.
  • Lead internal, external and regulatory audits for IT by preparing and presenting required documentation.
  • Lead initiatives for IT colleague and end-user education and communication on IT quality, security, and compliance.
  • Collaborate with various IT teams to ensure alignment of policies with technological advancements.
  • Maintain an in-depth understanding of evolving industry standards and regulatory requirements, advising the Executive Director on necessary policy adjustments.
  • Manage periodic reviews of GxP applications to verify their validated state and identify areas for improvement.
  • Collaborate with cross-functional teams to integrate compliance requirements into various IT initiatives, projects, and system implementations.
  • Monitor and evaluate changes in regulations and standards that could impact IT compliance, and work with the appropriate teams to implement necessary adjustments.
  • Conduct periodic audits, assessments, and internal reviews to validate the effectiveness of IT compliance measures and identify areas for improvement.
  • Report on key IT QC metrics, providing actionable insights to leadership.
  • Drive identification and resolution of QC-related issues. Work closely with relevant teams to implement corrective and preventive actions.
  • Lead IT quality and compliance training programs to ensure regulatory awareness and adherence across teams.
  • Develop and implement training materials for IT and business teams.
Desired Qualifications
  • Experience implementing / managing automated testing tools (suggested).
  • Consulting background a strong plus.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively combat bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to create broad-spectrum vaccines that can protect vulnerable populations from serious bacterial diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-1%
MarketBeat
Oct 5th, 2024
Clearbridge Investments LLC Makes New $14.06 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).

Bizjournals
Sep 20th, 2024
Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc.

In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.

Yahoo Finance
Sep 9th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock

Vaxcyte
Sep 6th, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte announces closing of $1.5 billion public offering including full exercise of underwriters' option to purchase additional shares.

GlobeNewswire
Sep 5th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte announces pricing of $1.3 billion public offering.